BioStem Technologies, Inc.
BSEM
NASDAQ·Healthcare·Biotechnology·Mkt cap $63.0M
$3.71
▲ +2.77%
P/E
-2.23
Mkt Cap
$63.0M
52-Wk Range
$2.25–$8.40
52-Week Range
$2.25 - $8.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 40.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-4.9% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BSEM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
Most recent quarter reported revenue of $7.9M (-84% YoY). Reported EPS of -$0.52.
Reported EPS · last 4Q
Q2 26
-$0.52
Q1 26
-$0.52
Q4 25
-$0.67
Q3 25
$0.05
Revenue trend · last 8Q
—
—
—
—
-87%
-182%
-92%
-84%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$82.6M
$102.9M
$72.5M
$49.3M
$10.5M
-$84.8M
$6.1M
$7.9M
Margins · last 8Q
Profit
-113.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BSEM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.